Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $18.50 Average Target Price from Analysts
Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Get Free Report) has been assigned an average recommendation of “Buy” from the seven brokerages that are currently covering the company, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year […]
Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Get Free Report) has been assigned an average recommendation of “Buy” from the seven brokerages that are currently covering the company, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year […]
